Venus Remedies will test APC-148 with various antibiotics against its extensive library of clinical isolates collected through the GASAR study

Norwegian pharmaceutical start-up company AdjuTec Pharma, a privately held company developing antibiotic resistance breakers, has entered into a research collaboration agreement with Venus Remedies. Venus Remedies will perform a pre-clinical evaluation of AdjuTec Pharma´s APC-148 platform technology.

AdjuTec Pharma has developed novel inhibitor technologies that selectively destroy antibiotic resistance mechanisms in multidrug-resistant bacteria, thereby restoring the effectiveness of commercially available antibiotics. APC-148 is the lead programme and it is presently in phase 1 clinical trials. As a frontrunner in antimicrobial resistance (AMR) research, Venus Remedies Limited will leverage its advanced R&D capabilities to assess APC-148’s potential in restoring the effectiveness of antibiotics against multidrug-resistant bacterial strains.

As part of this engagement, Venus Remedies will test APC-148 with various antibiotics against its extensive library of clinical isolates collected through the GASAR study. The study forms part of Venus Remedies’ broader commitment to combating AMR and contributing to the UN’s ‘One Health’ objective.

AdjuTec Pharma and Venus Remedies share a joint mission to address the global health threat against AMR.

AdjuTec Pharma, CEO, Jethro Holter said, “We are delighted to collaborate with Venus Remedies, a renowned Indian Company, with a shared purpose and commitment to develop more effective antibiotics to combat the escalating global AMR crisis. This agreement perfectly aligns with our strategy to collaborate with leading and international pharmaceutical partners to address the most clinically challenging resistant pathogens through our groundbreaking technology.”

Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre said, "We are pleased to collaborate with AdjuTec Pharma on the preclinical evaluation of APC-148. This research engagement allows us to contribute our expertise in AMR toward advancing scientific understanding of novel solutions in this space. Our collaboration reflects a shared commitment to addressing the global AMR challenge through rigorous, innovation-driven research.”